Impact of estrogen receptor expression level on response to neoadjuvant chemotherapy and prognosis in HER2-negative breast cancers
Abstract Background Breast cancers with 1–10% cell staining for estrogen receptor (ER) present particular clinical features. The clinical data of estrogen receptor expression level and treatment effect are limited, particularly regarding chemotherapy benefit. We evaluated the pathologic response to...
Auteurs principaux: | Hai-long Chen, Feng-bo Huang, Qiang Chen, Yong-chuan Deng |
---|---|
Format: | Article |
Langue: | English |
Publié: |
BMC
2023-09-01
|
Collection: | BMC Cancer |
Sujets: | |
Accès en ligne: | https://doi.org/10.1186/s12885-023-11368-2 |
Documents similaires
-
Estrogen receptor-negative/progesterone receptor-positive breast cancer has distinct characteristics and pathologic complete response rate after neoadjuvant chemotherapy
par: He Dou, et autres
Publié: (2024-01-01) -
Neoadjuvant chemotherapy with trastuzumab in HER2-positive breast cancer: pathologic complete response rate, predictive and prognostic factors
par: I.P.C. Buzatto, et autres -
Predictive factors for outcome in HER2-low breast cancer patients after neoadjuvant chemotherapy
par: Yingbo Shao, et autres
Publié: (2025-03-01) -
Clinicopathological characteristics and value of HER2-low expression evolution in breast cancer receiving neoadjuvant chemotherapy
par: Yingbo Shao, et autres
Publié: (2024-02-01) -
Association of tumor‐infiltrating lymphocytes before and after neoadjuvant chemotherapy with pathological complete response and prognosis in patients with breast cancer
par: Jin Hong, et autres
Publié: (2021-11-01)